Protocol Ledger

NCT06010004 · Phase III · COMPLETED

A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

Interventional Phase III clinical trial protocol NCT06010004 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-28 Enrollment: 401 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06010004
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)401 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06010004
Protocol FieldVerified Registry Value
NCT IdentifierNCT06010004
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment401 participants (ACTUAL)
Registered Start Date2023-09-28
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI